|Bid||0.00 x 800|
|Ask||200.00 x 1100|
|Day's Range||197.96 - 199.32|
|52 Week Range||149.69 - 199.32|
|PE Ratio (TTM)||18.75|
|Earnings Date||Oct 29, 2018 - Nov 2, 2018|
|Forward Dividend & Yield||2.00 (1.03%)|
|1y Target Est||203.00|
Now that AET has finally reached our target area a fresh look is certainly warranted and perhaps overdue. In this daily bar chart of AET, below, we can see that prices have been in an uptrend the past 12 months. The daily On-Balance-Volume (OBV) line has been moving up with the price action from early April.
Aetna has introduced the regional Aetna Whole Health - Southern California plan to employers with employees in San Diego County, Orange County, Los Angeles County and select portions of the Inland Empire.
The U.S. Department of Justice may not have plans to challenge the $69 billion mega-merger of CVS and Aetna. Dr. Theresa Rohr-Kirchgraber said the deal could severely limit patient choice when it comes to seeing a doctor or filling a prescription, and will almost certainly increase health-care costs by providing even less transparency into the already murky world of prescription drug prices. While the U.S. Department of Justice may not have plans to challenge the $69 billion mega-merger of CVS CVS and Aetna AET , patients and physicians should do so at every turn.
The pharmacy services giant reported strong prescription volume growth in the second quarter but a big writedown for its struggling LTC business.
The American Medical Association, which represents U.S. physicians, urged the U.S. Justice Department on Wednesday to stop CVS Health Corp's plan to buy insurance provider Aetna Inc, saying the deal could result in higher prices for prescription medicines. The AMA said that the $69 billion deal, announced in December, would lead to a "substantial reduction" of competition in pharmacy benefit (PBM) services market and the Medicare Part D prescription drug plan for seniors. The AMA said the deal would increase concentration in 10 of the 34 Medicare Part D regional markets to the point where it is presumed likely to increase market power.
Musk Pulls Nuclear Option on Tesla Shorts In quite a clever move that amounts to a surprise squeeze on Tesla (NASDAQ:TSLA) shorts, the notorious and constantly-in-the-news for one thing or another Tesla CEO Elon Musk proposed taking Tesla private yesterday, which rocketed shares higher 11%. The deal he proposed and says that he has somehow […] The post Market Morning: Musk Nukes Tesla Shorts, Negatively Priced Power, Samsung All In on AI appeared first on Market Exclusive.
CVS Health Corp. has dodged one hurdle in its bid to buy insurer Aetna Inc., as antitrust enforcers don’t see competitive problems that can stem from uniting companies that operate at different levels of a supply chain, according to two people familiar with the matter. The investigation by the Justice Department’s antitrust division hasn’t turned up vertical- competition concerns from the merger, according to the people, who declined to be identified because the review is confidential. CVS’s $68 billion deal to buy Aetna was announced on the heels of the Justice Department’s unsuccessful lawsuit to block AT&T Inc.’s takeover of Time Warner Inc., a vertical deal that combined a pay-TV distributor with a programmer.
Competitor Walgreens Boots Alliance (WBA) has also fallen 7.8% so far this year. Amazon’s (AMZN) foray into the pharma space with the PillPack acquisition, and the ongoing uncertainty arising from the Trump administration’s recommendations on how PBMs would receive rebates, has impacted drugstore stocks adversely. Amazon’s acquisition announcement of PillPack on June 28 resulted in respective declines of 6.0% and 9.0% in the stock prices of CVS Health and Walgreens.
Drug store giant CVS Health Corporation ( CVS) set its all-time intraday high of $113.65 at the end of July 2015 and has been a laggard since then. The pharmacy stock suffered under pressure from Amazon.com, Inc.'s ( AMZN) plan to expand into the healthcare industry. CVS stock traded as low as $60.14 on March 27 as the company countered with its plan to take over health insurer Aetna Inc. ( AET).
The dismantling of the Affordable Care Act (ACA), also known as Obamacare, and a deregulatory wave across affected states is underpinning profits, while the domestic focus of the health insurance companies is offering safe haven against trade war headwinds. Humana Inc. ( HUM) beat second quarter profit expectations by 18 cents while guiding fiscal year 2018 above consensus. Humana has competed with Dow component UnitedHealth Group Incorporated ( UNH) for industry leadership in recent years, matching rally leg for rally leg.
Aetna easily topped second-quarter earnings expectations as another drop in benefit expenses and lower taxes helped the nation's third-largest health insurer. Analysts expected, on average, $3.07 per share, according to Zacks Investment Research. Aetna didn't offer a 2018 forecast or discuss results with analysts Thursday due to its pending acquisition by the drugstore chain and pharmacy benefit manager CVS Health Corp. The companies announced that roughly $69-billion deal late last year and expect it to close in the second half of 2018.
Aetna (AET) delivered earnings and revenue surprises of 11.73% and 0.83%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
MARKET PULSE Aetna Inc. (AET) reported second-quarter profit and revenue beats early Thursday. Shares were inactive in premarket trade. Earnings for the latest quarter rose to $1.21 billion, or $3.67 per share, from $1.
Aetna announced second-quarter 2018 net income of approximately $1.2 billion, or $3.67 per share. Adjusted earnings for second-quarter 2018 were approximately $1.1 billion, or $3.43 per share.
On Thursday, Aetna (NYSE: AET ) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release. Earnings and Revenue Analysts predict Aetna ...
As global trade tensions play havoc with the financial markets, one strategy is to consider stocks with relatively large domestic sales exposure. This is the tactic recommended by Goldman Sachs. “Below the surface of the market, trade conflict would benefit the performance of the most domestic-facing U.S. stocks relative to the most foreign-facing firms,” the firm says. This is according to a recent warning from International Monetary Fund (IMF).
Amerigroup Kansas Inc. is taking legal action against the state of Kansas in conjunction with how three KanCare contracts were recently awarded. The company, based in Overland Park, filed a petition in court last week asking for a review of the state's request for proposals process.